{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT04644770","nct_id":"NCT04644770","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04644770. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.","label":"Part 1: Dose Escalation","type":"EXPERIMENTAL"},{"description":"Participants in one or more cohorts will receive JNJ-69086420 at the RP2D(s) determined in Part 1.","label":"Part 2: Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants will receive JNJ-69086420 at the determined RP2D(s) and fixed dose of JNJ-78278343.","label":"Part 3: Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants with HSPC will receive JNJ-69086420 at the RP2D(s) in Part 4(a), and JNJ-69086420 following stereotactic body radiation therapy in Part 4(b).","label":"Part 4: HSPC Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"conditions":["Prostatic Neoplasms","Adenocarcinoma"],"enrollment":{"count":144,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"JNJ-69086420","otherNames":["Actinium-225-DOTA-h11B6"],"type":"DRUG"},{"name":"JNJ-78278343","otherNames":[],"type":"DRUG"},{"name":"Stereotactic body radiation therapy","otherNames":[],"type":"RADIATION"}],"last_update":"2026-11-03","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-12-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability","timeFrame":"Up to 2 years and 4 months"},{"measure":"Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)","timeFrame":"Up to 2 years and 4 months"},{"measure":"Number of Participants with AEs by Severity","timeFrame":"Up to 2 years and 4 months"}],"references":[{"citation":"Lehner F, Salemi S, Millan C, Kundig C, Eberli D. Inhibition of Growth and Induction of Apoptosis of Human Prostate Cancer Cells by Enzymatic Blockage of Kallikreins. Prostate Cancer. 2026 Jan 11;2026:7871208. doi: 10.1155/proc/7871208. eCollection 2026.","pmid":"41531507","type":"DERIVED"}],"start_date":{"date":"2020-11-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04644770"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04644770"}